Compare STVN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | DNTH |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2021 | 2018 |
| Metric | STVN | DNTH |
|---|---|---|
| Price | $21.38 | $90.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $25.67 | ★ $121.00 |
| AVG Volume (30 Days) | 315.2K | ★ 625.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $9.67 | N/A |
| Revenue Next Year | $9.99 | $29.48 |
| P/E Ratio | $27.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.89 | $32.28 |
| 52 Week High | $27.99 | $117.88 |
| Indicator | STVN | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 33.61 |
| Support Level | $20.17 | $89.21 |
| Resistance Level | $22.00 | $97.60 |
| Average True Range (ATR) | 0.87 | 4.99 |
| MACD | -0.01 | -1.44 |
| Stochastic Oscillator | 50.09 | 18.61 |
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.